Cargando…

Development of a rapid functional assay that predicts GLUT1 disease severity

OBJECTIVE: To examine the genotype to phenotype connection in glucose transporter type 1 (GLUT1) deficiency and whether a simple functional assay can predict disease outcome from genetic sequence alone. METHODS: GLUT1 deficiency, due to mutations in SLC2A1, causes a wide range of epilepsies. One pos...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaman, Sasha M., Mullen, Saul A., Petrovski, Slavé, Maljevic, Snezana, Gazina, Elena V., Phillips, A. Marie, Jones, Gabriel Davis, Hildebrand, Michael S., Damiano, John, Auvin, Stéphane, Lerche, Holger, Weber, Yvonne G., Berkovic, Samuel F., Scheffer, Ingrid E., Reid, Christopher A., Petrou, Steven
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290489/
https://www.ncbi.nlm.nih.gov/pubmed/30588498
http://dx.doi.org/10.1212/NXG.0000000000000297
_version_ 1783380095676710912
author Zaman, Sasha M.
Mullen, Saul A.
Petrovski, Slavé
Maljevic, Snezana
Gazina, Elena V.
Phillips, A. Marie
Jones, Gabriel Davis
Hildebrand, Michael S.
Damiano, John
Auvin, Stéphane
Lerche, Holger
Weber, Yvonne G.
Berkovic, Samuel F.
Scheffer, Ingrid E.
Reid, Christopher A.
Petrou, Steven
author_facet Zaman, Sasha M.
Mullen, Saul A.
Petrovski, Slavé
Maljevic, Snezana
Gazina, Elena V.
Phillips, A. Marie
Jones, Gabriel Davis
Hildebrand, Michael S.
Damiano, John
Auvin, Stéphane
Lerche, Holger
Weber, Yvonne G.
Berkovic, Samuel F.
Scheffer, Ingrid E.
Reid, Christopher A.
Petrou, Steven
author_sort Zaman, Sasha M.
collection PubMed
description OBJECTIVE: To examine the genotype to phenotype connection in glucose transporter type 1 (GLUT1) deficiency and whether a simple functional assay can predict disease outcome from genetic sequence alone. METHODS: GLUT1 deficiency, due to mutations in SLC2A1, causes a wide range of epilepsies. One possible mechanism for this is variable impact of mutations on GLUT1 function. To test this, we measured glucose transport by GLUT1 variants identified in population controls and patients with mild to severe epilepsies. Controls were reference sequence from the NCBI and 4 population missense variants chosen from public reference control databases. Nine variants associated with epilepsies or movement disorders, with normal intellect in all individuals, formed the mild group. The severe group included 5 missense variants associated with classical GLUT1 encephalopathy. GLUT1 variants were expressed in Xenopus laevis oocytes, and glucose uptake was measured to determine kinetics (V(max)) and affinity (K(m)). RESULTS: Disease severity inversely correlated with rate of glucose transport between control (V(max) = 28 ± 5), mild (V(max) = 16 ± 3), and severe (V(max) = 3 ± 1) groups, respectively. Affinities of glucose binding in control (K(m) = 55 ± 18) and mild (K(m) = 43 ± 10) groups were not significantly different, whereas affinity was indeterminate in the severe group because of low transport rates. Simplified analysis of glucose transport at high concentration (100 mM) was equally effective at separating the groups. CONCLUSIONS: Disease severity can be partly explained by the extent of GLUT1 dysfunction. This simple Xenopus oocyte assay complements genetic and clinical assessments. In prenatal diagnosis, this simple oocyte glucose uptake assay could be useful because standard clinical assessments are not available.
format Online
Article
Text
id pubmed-6290489
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Wolters Kluwer
record_format MEDLINE/PubMed
spelling pubmed-62904892018-12-26 Development of a rapid functional assay that predicts GLUT1 disease severity Zaman, Sasha M. Mullen, Saul A. Petrovski, Slavé Maljevic, Snezana Gazina, Elena V. Phillips, A. Marie Jones, Gabriel Davis Hildebrand, Michael S. Damiano, John Auvin, Stéphane Lerche, Holger Weber, Yvonne G. Berkovic, Samuel F. Scheffer, Ingrid E. Reid, Christopher A. Petrou, Steven Neurol Genet Article OBJECTIVE: To examine the genotype to phenotype connection in glucose transporter type 1 (GLUT1) deficiency and whether a simple functional assay can predict disease outcome from genetic sequence alone. METHODS: GLUT1 deficiency, due to mutations in SLC2A1, causes a wide range of epilepsies. One possible mechanism for this is variable impact of mutations on GLUT1 function. To test this, we measured glucose transport by GLUT1 variants identified in population controls and patients with mild to severe epilepsies. Controls were reference sequence from the NCBI and 4 population missense variants chosen from public reference control databases. Nine variants associated with epilepsies or movement disorders, with normal intellect in all individuals, formed the mild group. The severe group included 5 missense variants associated with classical GLUT1 encephalopathy. GLUT1 variants were expressed in Xenopus laevis oocytes, and glucose uptake was measured to determine kinetics (V(max)) and affinity (K(m)). RESULTS: Disease severity inversely correlated with rate of glucose transport between control (V(max) = 28 ± 5), mild (V(max) = 16 ± 3), and severe (V(max) = 3 ± 1) groups, respectively. Affinities of glucose binding in control (K(m) = 55 ± 18) and mild (K(m) = 43 ± 10) groups were not significantly different, whereas affinity was indeterminate in the severe group because of low transport rates. Simplified analysis of glucose transport at high concentration (100 mM) was equally effective at separating the groups. CONCLUSIONS: Disease severity can be partly explained by the extent of GLUT1 dysfunction. This simple Xenopus oocyte assay complements genetic and clinical assessments. In prenatal diagnosis, this simple oocyte glucose uptake assay could be useful because standard clinical assessments are not available. Wolters Kluwer 2018-12-06 /pmc/articles/PMC6290489/ /pubmed/30588498 http://dx.doi.org/10.1212/NXG.0000000000000297 Text en Copyright © 2018 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology. This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND) (http://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Article
Zaman, Sasha M.
Mullen, Saul A.
Petrovski, Slavé
Maljevic, Snezana
Gazina, Elena V.
Phillips, A. Marie
Jones, Gabriel Davis
Hildebrand, Michael S.
Damiano, John
Auvin, Stéphane
Lerche, Holger
Weber, Yvonne G.
Berkovic, Samuel F.
Scheffer, Ingrid E.
Reid, Christopher A.
Petrou, Steven
Development of a rapid functional assay that predicts GLUT1 disease severity
title Development of a rapid functional assay that predicts GLUT1 disease severity
title_full Development of a rapid functional assay that predicts GLUT1 disease severity
title_fullStr Development of a rapid functional assay that predicts GLUT1 disease severity
title_full_unstemmed Development of a rapid functional assay that predicts GLUT1 disease severity
title_short Development of a rapid functional assay that predicts GLUT1 disease severity
title_sort development of a rapid functional assay that predicts glut1 disease severity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6290489/
https://www.ncbi.nlm.nih.gov/pubmed/30588498
http://dx.doi.org/10.1212/NXG.0000000000000297
work_keys_str_mv AT zamansasham developmentofarapidfunctionalassaythatpredictsglut1diseaseseverity
AT mullensaula developmentofarapidfunctionalassaythatpredictsglut1diseaseseverity
AT petrovskislave developmentofarapidfunctionalassaythatpredictsglut1diseaseseverity
AT maljevicsnezana developmentofarapidfunctionalassaythatpredictsglut1diseaseseverity
AT gazinaelenav developmentofarapidfunctionalassaythatpredictsglut1diseaseseverity
AT phillipsamarie developmentofarapidfunctionalassaythatpredictsglut1diseaseseverity
AT jonesgabrieldavis developmentofarapidfunctionalassaythatpredictsglut1diseaseseverity
AT hildebrandmichaels developmentofarapidfunctionalassaythatpredictsglut1diseaseseverity
AT damianojohn developmentofarapidfunctionalassaythatpredictsglut1diseaseseverity
AT auvinstephane developmentofarapidfunctionalassaythatpredictsglut1diseaseseverity
AT lercheholger developmentofarapidfunctionalassaythatpredictsglut1diseaseseverity
AT weberyvonneg developmentofarapidfunctionalassaythatpredictsglut1diseaseseverity
AT berkovicsamuelf developmentofarapidfunctionalassaythatpredictsglut1diseaseseverity
AT schefferingride developmentofarapidfunctionalassaythatpredictsglut1diseaseseverity
AT reidchristophera developmentofarapidfunctionalassaythatpredictsglut1diseaseseverity
AT petrousteven developmentofarapidfunctionalassaythatpredictsglut1diseaseseverity